IXIFI Trademark
IXIFI is a USPTO trademark filed by Pfizer Inc.. Status: Pending.
Prosecution Summary
Trademark Summary
The standard character mark IXIFI covers pharmaceutical preparations in International Class 005 for treating autoimmune, cardiovascular, and other diseases and disorders, including anti-infectives, medicated dermatologicals, smoking cessation preparations, and vaccines for human use, with additional domestic classes 006, 018, 044, 046, 051, and 052. It is owned by Pfizer Inc., a Delaware corporation based in New York. The application is new and awaiting assignment to an examining attorney, filed on an intent-to-use basis and claims prior registration No. 6013722.
Recent Activity
Pfizer Inc. filed the application on February 10, 2026. The USPTO entered new application data and mailed the filing receipt on the same date.
Trademark Facts
| Mark | IXIFI |
|---|---|
| Serial Number | 99644651 |
| Status | Pending |
| Filing Date | 2026-02-10 |
| Mark Type | Word |
| Nice Classes | 005 (Pharmaceuticals) |
| Owner | Pfizer Inc. |
| Attorney of Record | Andrea Christensen |
| Prosecution Events | 3 |
| Latest Event | MAFR on 2026-02-10 |
Goods & Services
Class 005: Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; Pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; Pharmaceuticals, namely, anti-infectives; Medicated dermatological preparations and substances; Smoking cessation preparations; Vaccines for human use